BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14625662)

  • 1. 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases.
    Garcia JR; Simo M; Perez G; Soler M; Lopez S; Setoain X; Lomeña F
    Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1714. PubMed ID: 14625662
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
    Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
    Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
    Sahin E; Zincirkeser S; Akcan AB; Elboga U
    J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography.
    Foo SS; Ramdave S; Berlangieri SU; Scott AM
    Australas Radiol; 2004 Jun; 48(2):214-6. PubMed ID: 15230758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and (99m)Tc-MDP whole-body bone scanning for imaging osteolytic bone metastases.
    Zhang L; Chen L; Xie Q; Zhang Y; Cheng L; Li H; Wang J
    BMC Med Imaging; 2015 Mar; 15():7. PubMed ID: 25885599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metastases diagnosis possibilities in studies with the use of 18F-NaF and 18F-FDG.
    Tarnawska-Pierścińska M; Hołody Ł; Braziewicz J; Królicki L
    Nucl Med Rev Cent East Eur; 2011; 14(2):105-8. PubMed ID: 22219151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
    Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I
    J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases.
    An YS; Yoon JK; Lee MH; Joh CW; Yoon SN
    Clin Nucl Med; 2005 Mar; 30(3):203-4. PubMed ID: 15722832
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
    Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
    J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm.
    Pezeshk P; Sadow CA; Winalski CS; Lang PK; Ready JE; Carrino JA
    Acad Radiol; 2006 Aug; 13(8):1011-5. PubMed ID: 16843854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy.
    Ohta M; Tokuda Y; Suzuki Y; Kubota M; Makuuchi H; Tajima T; Nasu S; Suzuki Y; Yasuda S; Shohtsu A
    Nucl Med Commun; 2001 Aug; 22(8):875-9. PubMed ID: 11473206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F-FDG PET and bone scintigraphy to search for bone metastasis of lung cancer].
    Aflalo-Hazan V; Gutman F; Raileanu I; Frétault J; Kerrou K; Grahek D; Montravers F; Talbot JN
    Rev Pneumol Clin; 2006 Jun; 62(3):164-9. PubMed ID: 16840993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
    Schirrmeister H; Guhlmann A; Elsner K; Kotzerke J; Glatting G; Rentschler M; Neumaier B; Träger H; Nüssle K; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1623-9. PubMed ID: 10520701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.